EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Immunosuppression and cancer risk in kidney transplant recipients: A retrospective cohort study

Ruth Sapir-Pichhadze iD, Claudie Laprise, Marie-Eve Beauchamp, Mohammed Kaouache, Xun Zhang, Alexia Della Vecchia, Laurent Azoulay iD, Eduardo L Franco iD, Michal Abrahamowicz, Belinda Nicolau

International Journal of Cancer · 15.06.2024 · 154 (12) · 2043-2053

DOI: 10.1002/ijc.34875 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift International Journal of Cancer, online erschienen am 12.02.2024. Verfasst von Ruth Sapir-Pichhadze und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Outcomes Research and Evaluation, Research Institute of McGill University Health Centre, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Kidney Transplantation, Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Fonds de Recherche du Québec - Santé, Genome Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We assessed whether contemporary immunosuppression agents were associated with cancer among kidney transplant recipients (KTR), and if this association varied by age and sex. We studied a retrospective province‐wide cohort of primary KTR (1997–2016). Employing multivariable Cox models, we estimated associations of cumulative doses of prednisone, mycophenolate and tacrolimus administered over the past 10 years, lagged by 2 years, with the incidence of primary malignant neoplasms (PMN). We assessed interactions with age and sex. To assess the impact of exposure recency, we used weighted cumulative exposure (WCE) modeling. Among 1064 KTR, 108 (10.2%) developed PMN over median follow‐up of 73 months (interquartile range: 32–120). Adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) of 0.96 (0.64–1.43), 1.34 (0.96–1.86), and 1.06 (0.88–1.29) were estimated for cumulative daily doses of prednisone (5 mg), mycophenolate (1000 mg), and tacrolimus (2 mg) administered continuously over the past 10 years, respectively. PMN risk associated with cumulative tacrolimus exposure was modified by age (interaction p = .035) and was more pronounced in 15‐year and 30‐year‐old KTR (aHRs of 1.57 [1.08–2.28] and 1.31 [1.03–1.66], respectively) in comparison to older KTR. PMN risk increase associated with higher cumulative mycophenolate dose was more pronounced in females (aHR = 1.86 [1.15–3.00]) than in males (aHR = 1.16 [0.74–1.81]; interaction p = .131). WCE analyses suggested increased PMN risk the higher the mycophenolate doses taken 5–10 years ago. A trend toward increased PMN risk with long‐term mycophenolate exposure, particularly in females, and more pronounced risk with long‐term tacrolimus exposure in younger KTR, identify opportunities for tailored immunosuppression to mitigate cancer risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationNeoplasmsMaleFemaleHumansAdolescentTacrolimusRetrospective StudiesPrednisoneMycophenolic AcidGraft RejectionImmunosuppressive AgentsImmunosuppression TherapyEnzyme InhibitorsTransplant Recipients

Stichwörter der Autor:innen

agecancerimmunosuppressionkidney transplantationsex

Substanzen

TacrolimusPrednisoneMycophenolic AcidImmunosuppressive AgentsEnzyme Inhibitors

Autor:innen und Institutionen

  • Centre for Outcomes Research and Evaluation, Research Institute of McGill University Health Centre, Montreal, Quebec, Canada.
  • Department of Epidemiology, Biostatistics, Occupational Health, McGill University, Montreal, Quebec, Canada.
  • Division of Nephrology, Department of Medicine, McGill University, Montreal, Quebec, Canada.
  • Department of Social and Preventive Medicine, Université de Montréal, Montreal, Quebec, Canada.
  • Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, Quebec, Canada.
  • Division of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada.

ORCID-Profile: Ruth Sapir-Pichhadze, Laurent Azoulay, Eduardo L Franco

Förderung

  • CIHR
  • Fonds de Recherche du Québec - Santé
  • Genome Canada
  • Canadian Institutes of Health Research

Zitieren

APA

Sapir-Pichhadze, R., Laprise, C., Beauchamp, M. E., Kaouache, M., Zhang, X., Della Vecchia, A., Azoulay, L., Franco, E. L., Abrahamowicz, M., & Nicolau, B. (2024). Immunosuppression and cancer risk in kidney transplant recipients: A retrospective cohort study. International Journal of Cancer, 154(12), 2043-2053. https://doi.org/10.1002/ijc.34875

Vancouver

Sapir-Pichhadze R, Laprise C, Beauchamp ME, Kaouache M, Zhang X, Della Vecchia A, et al. Immunosuppression and cancer risk in kidney transplant recipients: A retrospective cohort study. International Journal of Cancer. 2024;154(12):2043-2053. doi:10.1002/ijc.34875

BibTeX
@article{SapirPichhadze2024,
  author = {Sapir-Pichhadze, Ruth and Laprise, Claudie and Beauchamp, Marie-Eve and Kaouache, Mohammed and Zhang, Xun and Della Vecchia, Alexia and Azoulay, Laurent and Franco, Eduardo L and Abrahamowicz, Michal and Nicolau, Belinda},
  title = {Immunosuppression and cancer risk in kidney transplant recipients: A retrospective cohort study},
  journal = {International Journal of Cancer},
  year = {2024},
  volume = {154},
  number = {12},
  pages = {2043--2053},
  doi = {10.1002/ijc.34875}
}
Kostenlos starten →